RNA modifications in cancer immune therapy: regulators of immune cells and immune checkpoints

Area of Science:

• Oncology
• Immunology
• Epigenetics

Background:

• RNA modifications are epigenetic regulators influencing gene expression and cellular function.
• Immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment but exhibit limited patient sensitivity.
• Understanding RNA modifications in the tumor microenvironment is crucial for improving immunotherapy outcomes.

Purpose of the Study:

• To comprehensively review the functions and therapeutic implications of major RNA modifications in cancer.
• To highlight the specific role of N6-methyladenosine (m6A) in immune cells and its impact on cancer immunotherapy.
• To explore the potential of targeting RNA modifications for novel cancer treatment strategies.

Main Methods:

• Literature review of RNA modifications in cancer and immunology.
• Analysis of the role of RNA modifications in immune cell function (T cells, NK cells, macrophages, dendritic cells).
• Examination of RNA modification influence on immune checkpoint expression and ICI efficacy.

Main Results:

• RNA modifications significantly affect immune cell behavior and function within the tumor microenvironment.
• N6-methyladenosine (m6A) plays a critical role in regulating immune checkpoint expression and modulating responses to ICIs.
• RNA modifications can predict patient responses to ICI therapy and offer targets for drug development.

Conclusions:

• RNA modifications, particularly m6A, are key regulators in cancer immunity and immunotherapy.
• Targeting RNA modifications holds promise for enhancing ICI efficacy, developing predictive biomarkers, and advancing cancer vaccines and cell therapies.
• Further research into RNA modification-based strategies could significantly improve cancer patient outcomes.